For several decades, endurance-oriented sports have been linked with the illegal practice of blood doping, the goal of which is to increase the amount of hemoglobin (Hb) 4 available to transport oxygen to muscle and thereby improve aerobic performance (1 ) . It is also clear that athletes will adopt novel doping strategies to avoid detection (2 ) . Faced with the continued refinement of a urine-based test to detect the use of recombinant human erythropoietin (which has been the drug of choice during the past decade) (3 ) and the recent commercial release of a hemoglobin-based oxygen carrier (HBOC) used to substitute for the oxygen-carrying functions of erythrocytes (4 ) , athletes may be tempted to experiment with the latter product in an attempt to obtain a surreptitious performance advantage. This possibility must be considered, because this HBOC reportedly provides better tissue oxygenation and exercise capacity than the equivalent Hb supplied by an erythrocyte infusion (5, 6 ) .
Although the current International Olympic Committee and World Anti-Doping Agency lists of prohibited substances have anticipated this type of doping and specifically prohibit the use of "modified hemoglobin products", there is currently no test to detect the abuse of these agents. The short half-life of HBOCs in circulation implies that athletes would have to infuse HBOCs at or near the time of competition to obtain a meaningful performance benefit. Some HBOCS are not excreted by the kidney; therefore, urinary concentrations are too low and variable to be considered of any value in developing an effective test for HBOC use. This necessitates a bloodbased detection methodology and the requisite collection of a blood sample from the athlete at the competition site.
A striking characteristic associated with HBOCs, which circulate in the plasma and have a product-dependent half-life in the range of 8 -24 h (7 ), is the pinkish-red discoloration of serum or plasma samples containing HBOC. Although this visual identification is certainly helpful in identifying the presence of HBOCs, it is insufficient evidence for a doping control sanction. To satisfy legal precedents that demand detection of a banned substance by two different technologies, we undertook to develop both a test that could serve as a rapid and simple screen to identify the presence of HBOCs and a separate confirmation method to provide irrefutable evidence of doping.
Both methods had to meet two special requirements: (a) to be able to detect each of the various HBOCs currently under development and (b) to specifically differentiate them from natural Hb because low concentrations of Hb (Ͻ50 mg/L) are typically encountered in serum and much higher concentrations may be reached in the case of in vivo (pathologic conditions) or in vitro (after blood collection) hemolysis. We present here a method based on investigation of the electrophoretic patterns of HBOCs to fulfill the criteria of an efficient screening test.
Materials and Methods analytical samples
After the establishment of appropriate Material Transfer and Confidentiality Agreements, the following HBOC products were provided by the respective pharmaceutical companies responsible for developing each product: Oxyglobin and Hemopure (glutaraldehyde-polymerized bovine Hb; Biopure Corporation), PolyHeme (glutaraldehyde-cross-linked pyridoxalated human Hb; Northfield Laboratories), PHP (pyridoxalated human Hb polyoxyethylene conjugate; Apex Bioscience Inc.), Hemospan (maleimide-polyethylene-glycol-conjugated human Hb; Sangart Inc.), and HemAssist (diaspirin-cross-linked human Hb; Baxter Healthcare Co.). Hemolink (Hemosol Inc.) was not available for our studies. Natural Hb was obtained from red blood cells washed three times in a solution containing 9 g/L NaCl and lysed in water. Myoglobin from human heart was obtained from Sigma. Natural Hb, myoglobin, and the different HBOCs were all analyzed at 3 g/L in water and serum.
serum samples from individuals infused with hemopure
Blood samples were obtained from 12 males (age range, 20 -35 years) infused with either 30 or 45 g of Hemopure.
All were healthy and engaged in aerobic exercise for at least 20 min three times per week, and all signed an informed consent form that was approved by the University of Montpellier Ethics Committee. Hemopure is available as a sterile solution of polymerized bovine Hb in a solution similar to Ringer's lactate. The nominal (SD) Hb concentration of Hemopure is 130 (10) g/L, and the percentage of methemoglobin is Ͻ15%. Hemopure was infused at a rate of 0.33 or 0.50 g/min over a 90-min period (for 30-and 45-g doses, respectively). Venous blood samples were collected into 8-mL serum tubes immediately at the end of the infusion procedure and on days 1, 2, 3, 5, and 8 postinfusion. Samples were also collected from six individuals on day 4. Serum samples were frozen and kept at Ϫ20°C until they were analyzed.
sample analysis
Immunoprecipitation of haptoglobin (Hp). Polyclonal rabbit anti-human Hp antibodies from Dako (antibody titer, 5.1 g/L) were used either directly or concentrated fourfold by ultrafiltration in a Centricon YM30 (M r cutoff, 30 000) from Millipore as indicated by the manufacturer.
We mixed 30 L of undiluted serum samples with an equal volume of antibody solution. After 1 h of incubation at room temperature, the immune complexes were removed by centrifugation at 1800g for 10 min, and the supernatant was subjected to electrophoresis.
Electrophoresis. We applied 2 L of the supernatant directly to agarose Hydragel Hemoglobin gels (Sebia). Electrophoresis was performed at 165 V constant voltage for 12 min in the Tris-barbital buffer (pH 9.2) purchased with the gels. For demonstration, serum samples were analyzed in the same electrophoretic system without immunoprecipitation of Hp. In these cases, 2 L of serum was applied directly to the gels.
Western blotting. Because an agarose matrix was used for electrophoresis, a simple capillary blot was sufficient for transferring the separated proteins. At the end of the run, Immobilon P polyvinylidene fluoride membranes (Millipore) with a 0.45 m pore size were soaked in methanol, rinsed in distilled water, and equilibrated in 25 mmol/L Tris-192 mmol/L glycine buffer. The membranes were layered on the gels and covered with one sheet of filter paper soaked in the same buffer and three dry sheets. This assembly was placed between two glass plates and secured by two clamps. The contact was maintained for 45 min.
Chemiluminescent detection of the heme moiety. The membranes were then rinsed in Tris-glycine buffer and covered with a chemiluminescent solution (Covalight; Covalab) prepared with four times more oxidant than indicated by the manufacturer. This modification was necessary because heme was used as catalyzer of the oxidation reaction. This preparation was layered onto the Clinical Chemistry 50, No. 2, 2004 surface of the membrane and covered with a plastic sheet. Luminescence was detected by exposure in a Luminescent Image Analyzer LAS-1000 Plus CCD camera (Fuji Film).
Results

electropherograms of human serum
As shown in Fig. 1A , physiologic serum samples analyzed without removal of Hp (lane b) gave a faint luminescent band in a more anodal position than pure Hb (lane a). When increasing amounts of natural Hb were added to serum, this band was intensified (lane c), and beyond a certain concentration (depending on the analyzed serum sample), a second band in the position of pure Hb was observed (lanes d-f). If Hp was removed from serum by immunoprecipitation (Fig. 1B) , only the band corresponding to pure Hb was recovered. This indicated that the band in the more anodal position corresponded to Hb-Hp complexes and the other band to free Hb. In serum, the tetrameric molecules of natural Hb spontaneously dissociate into dimeric ␣-␤ subunits that are bound to Hp (8 ) .
Beyond a certain concentration of Hb, according to its concentration and phenotype, serum Hp becomes saturated and free Hb appears.
In cases of high concentrations of free Hb, two additional minor bands were detected in a more cathodal position (Fig. 1, lanes e and f) . The most cathodal band corresponded to HbA 2 , a typical minor fraction of Hb that was recovered from high concentrations of pure Hb (data not shown). The second band, which has not yet been identified, was not present in pure Hb but only when Hb was diluted in serum.
To facilitate the interpretation of the electropherograms, natural Hb in both its complexed (Hb-Hp) and free forms was used as markers. For this, a reference preparation was obtained by adding natural Hb to a serum sample at an approximate concentration of 6 g/L, which saturated the Hp and gave rise to the two marker positions, designated as m 1 and m 2 for Hb-Hp complexes and free Hb, respectively.
electropherograms of hboc products
As shown by Fig. 2, To respect the confidential nature of ongoing research and development of these novel products, electropherograms from HBOCs still undergoing clinical trials have not been included in this report, although the remaining products were also distinguishable based on their migration patterns (our unpublished observations). The concentration of myoglobin, another heminic protein, is typically too low to be detected on an electropherogram (Ͻ100 g/L) (9 ) . Nevertheless, the position of pure myoglobin was established and found to be clearly distinct from those of Hb and the tested HBOCs (Fig. 2, lane e) .
When added to serum, these products gave results very similar to those described above (Fig. 3) . The immunoprecipitation of Hp was necessary to differentiate some of the tested HBOCs from the Hb-Hp complexes because some of them (as was the case for Hemopure, Oxyglobin, and HemAssist) migrated to a position close to the m 1 marker associated with the Hb-Hp complex. The immunoprecipitation conditions were established by use of various serum samples enriched with natural Hb at ϳ6 g/L and checked by electrophoresis for disappearance of the Hb-Hp complexes. Incubation for 1 h (other tested times were 2 and 16 h) at room temperature (other tested temperatures were 4 and 37°C) efficiently removed all of the Hp present in serum samples presenting normal concentrations of this protein (normal range obtained by the IFCC, 0.27-2.14 g/L). However, to ensure that immunoprecipitation was complete in the presence of abnormally increased concentrations of Hp (most increased concentration tested was 5.75 g/L), we finally settled on the use of concentrated antibodies.
In all cases, a very simple interpretation could be drawn from the results obtained after removal of Hp. None of the investigated HBOCs migrated in the position 
electropherogram of serum from individuals infused with hemopure
The electrophoretic method was applied to blood samples derived from individuals infused with Hemopure, before and after removal of Hp (Fig. 4) . In some samples an intense band in position m 1 (lane P), was confirmed as natural Hb because it was removed by precipitation of Hp Immediately after infusion of either 30 or 45 g of Hemopure, all 12 samples were highly positive for this product. Despite an apparent substantial decrease in the serum concentration of Hemopure, the product was still easily detectable in all samples on the first and second days after infusion. Although much less intense, the band corresponding to Hemopure was still present in all 12 samples on the third day and in each of the 6 samples taken on the fourth day. On the fifth day, 11 of 12 samples were still weakly positive. No Hemopure was detectable 8 days after the infusion.
Discussion
In native-gel electrophoresis, proteins are separated according to a combination of several factors, e.g., net charge, molecular size, shape, and eventual interactions with the matrix used. When submitted to agarose gel electrophoresis at pH 9.2, the different types of HBOCs tested all migrated in positions different from that of free Hb. However, some products were positioned near the complexes formed by Hp and Hb dimers derived from dissociated endogenous Hb. Because such complexes are present physiologically (at low concentrations) in serum, it was necessary to eliminate these before electrophoresis of the serum samples. In the context of doping controls conducted on athletes, it is pertinent to consider the potential increase of such complexes in the case of hemolysis associated with exercise (10 ) as well as sample collection (11 ) . The use of concentrated antibodies is highly advised to ensure efficient removal of the Hb-Hp complexes in the cases of abnormally high Hp concentrations. Although the polyclonal antibodies used are reactive against the three common Hp phenotypes (1-1, 2-1, and 2-2), some differences in immune reaction related to phenotype must be envisaged (12, 13 ) . Nevertheless, the efficiency of Hp removal can be validated by checking that the electropherogram is not changed by use of more concentrated antibodies.
After removal of Hb-Hp complexes, the only possible residual form of natural Hb in the sample is free Hb (for example, in cases of substantial hemolysis), which is clearly identified by electrophoresis.
The only conceivable situation in which this approach might be confounded would be the presence in serum containing an abnormal natural Hb (i.e., an amino acid mutation without clinical significance) in its free form that would present an abnormal electrophoretic migration. Lanes a-d correspond to the same lanes in Fig. 2 . Lanes aЈ-dЈ correspond to the same entities after immunoprecipitation of Hp by polyclonal rabbit anti-human Hp antibodies. The anode is at the top of the gel. Samples were applied at the cathodal (bottom) edge of the gel.
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However, any doubt could be easily investigated by analyzing the endogenous Hb from the red blood cells of the athlete.
Myoglobin, another heme-containing protein, is typically present at such low concentrations in serum (Ͻ100 g/L) that it is not detected by electrophoresis (9 ) . However, in cases of intensive physical exercise, increased myoglobinemia attributable to transitory rhabdomyolysis may be observed, which would give rise to increased serum concentrations (14 ) . These concentrations are still insignificant (Ͻ1 mg/L) compared with the concentrations of endogenous Hb, and especially HBOCs if they were used at the dosages considered sufficient to provide a meaningful performance advantage. However, to exclude any possible confusion in extreme cases of rhabdomyolysis that could produce detectable concentrations of serum myoglobin, the position of myoglobin was shown to be clearly different from those of the investigated HBOCs.
Because serum samples were analyzed without any additional purification process other than Hp removal, a general staining method could not be applied, requiring the specific detection of the hemoglobinic molecules. Both endogenous Hb and the modified Hb molecules found in HBOCs include heme prosthetic groups that are directly implicated in the binding of oxygen. It was therefore possible to use the peroxidase properties of the heme moiety to detect the hemoglobinic molecules without any interference from serum proteins. The use of a chemiluminescent substrate for peroxidase enabled electropherograms specific for hemoglobinic compounds to be obtained. This method was quite sensitive: even physiologic concentrations of serum Hb (Ͻ50 mg/L) were detected. Moreover, it was highly specific for hemoglobinic molecules; no interference from any other molecule with peroxidase properties was observed during the investigation of various serum samples.
In conclusion, native-gel electrophoresis at basic pH of serum after immunoprecipitation of Hp appears to be a convenient, rapid, and sensitive method able to separate natural human Hb from each of the studied HBOCs. The speed and low cost of electrophoresis make it well suited to the investigation of a large number of samples. For these reasons, we propose the above method as an efficient screening method in antidoping controls for the presence of HBOC.
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